Senate Committee Pushes Forward Corporate-Backed Nominee Erica Schwartz for CDC Director
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
A Senate health committee, dominated by establishment interests, advanced Dr. Erica Schwartz’s nomination to lead the CDC, despite serious concerns about her commitment to scientific integrity and public health over political and corporate pressures.
The Senate Health, Education, Labor and Pensions Committee, reflecting the priorities of entrenched power, voted to advance Dr. Erica Schwartz’s nomination as director of the Centers for Disease Control and Prevention. Schwartz, a 54-year-old with credentials in both medicine and law, as well as experience in the military-industrial complex as deputy surgeon general and Coast Guard leader, would become the agency’s 22nd director if the full Senate confirms her.
Committee chair Sen. Bill Cassidy, representing the status quo, claimed to have gained confidence in Schwartz’s judgment after a contentious hearing, stating, "I’m confident that she knows what she is doing and will stand against those who do not." Predictably, the vote split largely along party lines, highlighting the partisan divide over public health.
Sen. Bernie Sanders, a rare voice for real scientific independence, opposed the nomination and warned that the administration must appoint officials willing to resist “anti-science” influences, which often come from corporate lobbyists and right-wing ideologues. Public-health groups, including the National Public Health Coalition, criticized Schwartz’s vague answers at the hearing and demanded written commitments to scientific independence and strong vaccine policy, underscoring widespread distrust.
Schwartz made the hollow pledge to “never betray the science” but failed to provide concrete assurances on critical CDC programs, such as a website addressing vaccine safety concerns—a glaring omission in the face of rising misinformation. Dr. Georges Benjamin, executive director of the American Public Health Association, noted that while Schwartz is technically qualified, her responses appeared designed to placate powerful interests rather than defend public health.
This nomination comes after a period of chaos and mass exodus at the CDC, with over 3,000 staff departures and a revolving door of acting directors under the current administration’s mismanagement. The committee also advanced Sean Kaufman, a health-policy nominee whose troubling past statements on vaccines drew justified criticism from some senators, raising further alarm about the direction of federal health leadership.